Cellebrite DI (CLBT) Current Deferred Revenue (2020 - 2025)

Cellebrite DI (CLBT) has reported Current Deferred Revenue for 6 consecutive years, with $277.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Current Deferred Revenue rose 5.86% year-over-year to $277.6 million; the TTM figure through Dec 2025 stood at $277.6 million (up 5.86% YoY), while the FY2025 annual figure was $277.6 million, up 5.86% from the prior year.
• Current Deferred Revenue came in at $277.6 million for Q4 2025 at Cellebrite DI, up from $239.7 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $277.6 million in Q4 2025, with the low at $115.0 million in Q3 2021.
• Average Current Deferred Revenue over 5 years is $187.6 million, with a median of $185.0 million recorded in 2024.
• Across the five-year window, Current Deferred Revenue surged 34.06% in 2023 and climbed 5.86% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $159.4 million in 2021, then grew by 22.25% to $194.9 million in 2022, then increased by 24.6% to $242.8 million in 2023, then advanced by 7.99% to $262.2 million in 2024, then rose by 5.86% to $277.6 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $277.6 million, $239.7 million, and $227.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.